MedDataX Logo

Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients

NCT ID: NCT00768196

Last Updated: 2010-12-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-09-30

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to asses the EED symptom prevalence in Koran GERD patients with typical reflux symptom and to evaluate quality of life with the scales including Gerd Q.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroesophageal Reflux Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

GERD Korea typical symptom quality of life Naturalistic epidemiological

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* GERD patients who have experienced heartburn or acid regurgitation during past 7 days
* GERD patients who have already undergone endoscopy before enrolment

Exclusion Criteria

* Involvement in the planning and conduct of the programme
* The person who took the medicine such as PPI or H2RA during the last 7 days
* Severe systemic disease
Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joon-Woo Bahn

Role: STUDY_DIRECTOR

AstraZeneca Korea

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Cheonan, Chungcheongnam-do, South Korea

Site Status

Research Site

Seoul, Kyungkido, South Korea

Site Status

Research Site

Sungnam, Kyungkido, South Korea

Site Status

Research Site

Suwon, Kyungkido, South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-GKR-DUM-2008/1

Identifier Type: -

Identifier Source: org_study_id